El Hospital de Dénia participates in a clinical trial to administer intravenous immunoglobulin to patients with COVID-19, admitted to the health center and who require oxygen therapy. In the trial, promoted by the Catholic University of Murcia, the hospitals of Torrevieja and Vinalopó, in Alicante; that of Torrejón de Ardoz, in Madrid and that of Povisa in Pontevedra.
The clinical trial is randomized and double-blind in order not to bias the results, neither by the physician nor by the patient, since neither party knows whether the medication administered corresponds to the immunoglobulin or not. The information is only held by the Hospital Pharmacy Service, which is the one who performs the randomization and supplies the medication with the same format but different content.
At the moment the Hospital de Dénia is in the recruitment phase of cases that are previously informed and requests a written consent of acceptance of the clinical trial. All of them are treated with current protocols already established with drugs that have already demonstrated clinical effectiveness and that, today, are basically corticosteroids and supportive management with oxygen therapy and prophylactic or full anticoagulation depending on the cases.
According to the Director of Hospitalization of the Hospital de Dénia, Dr. Patricia Martín Rico, “The trial will be carried out over the next six months and its effectiveness will be verified during that time. Intravenous immunoglobulin, given in large doses, has an anti-inflammatory effect. "" We know. ", adds Martín Rico, "that COVID-19 triggers an inflammatory storm, which is the one that damages tissues; so that immunoglobulin could be an effective therapeutic measure".
